Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 6/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5306190 | 0.80 | CYP3A4 (0.55) | CYP3A4CYP1A2CYP2D6CYP2C19CYP2C9 | |
| SCHEMBL8815628 | 0.78 | GAA (0.50) | CYP3A4CYP1A2CYP2D6CYP2C19CYP2C9 | |
| SCHEMBL28678423 | 0.78 | CYP3A4 (0.59) | CYP3A4CYP1A2CYP2D6CYP2C19CYP2C9 | |
| SCHEMBL4878557 | 0.78 | LMNA (0.56) | CYP3A4CYP1A2CYP2D6CYP2C19CYP2C9 | |
| SCHEMBL30753599 | 0.78 | LMNA (0.56) | CYP3A4CYP1A2CYP2D6CYP2C19CYP2C9 | |
| SCHEMBL21863403 | 0.78 | CYP3A4 (0.46) | CYP3A4CYP1A2CYP2D6CYP2C19CYP2C9 | |
| SCHEMBL17443527 | 0.76 | GRIN2D (0.41) | KMT2AALDH1A1MAPT | |
| SCHEMBL29486491 | 0.76 | GRIN2D (0.45) | MAPK1ALDH1A1MAPT | |
| SCHEMBL2649367 | 0.76 | GRIN2D (0.45) | MAPK1ALDH1A1MAPT | |
| SCHEMBL16381986 | 0.76 | PIM1 (0.32) | CYP3A4CYP1A2CYP2D6CYP2C19CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4676547-A2 | ALPHA-SYNUCLEIN BINDERS AND METHODS OF USE | Merck Sharp & Dohme LLC (US) | 2026-01-14 | — | — | EP | disclosed |
| US-20250296915-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2025-09-25 | — | — | US | disclosed |
| US-20240425478-A1 | CYCLOPENTYLPYRAZOLE CDK2 INHIBITORS | GENENTECH INC (US) | 2024-12-26 | — | — | US | disclosed |
| WO-2024186584-A2 | ALPHA-SYNUCLEIN BINDERS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-09-12 | — | — | WO | disclosed |
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | RAQUALIA PHARMA INC. (JP) | 2023-10-31 | — | — | US | disclosed |
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | RAQUALIA PHARMA INC. (JP) | 2023-10-31 | — | — | US | disclosed |
| EP-3774739-B1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC (JP) | 2022-05-11 | — | — | EP | disclosed |
| US-20210078975-A1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC. (JP) | 2021-03-18 | — | — | US | disclosed |
| US-20100286211-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | RANBAXY LABORATORIES LIMITED (IN) | 2010-11-11 | — | — | US | disclosed |
| EP-1799677-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | Ranbaxy Laboratories Limited (IN) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006038100-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | RANBAXY LABORATORIES LIMITED (IN) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240425478-A1 | CYCLOPENTYLPYRAZOLE CDK2 INHIBITORS | CDK2, CCNI, CDK20 | CYP3A4 414/4885CYP1A2 960/4885CYP2D6 343/4885 |
| US-20100286211-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | OXA1L, PDK4, MLYCD | CYP3A4 207/4885CYP1A2 1058/4885CYP2D6 295/4885 |
| US-20250296915-A1 | NOVEL AMINO ACID DERIVATIVES | DNPEP, BCAT1, ANPEP | CYP3A4 4395/4885CYP1A2 4816/4885CYP2D6 4642/4885 |
| US-20210078975-A1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | CRHR2, CRHR1, CRH | CYP3A4 4562/4885CYP1A2 3484/4885CYP2D6 4316/4885 |
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | CRHR2, CRHR1, CRH | CYP3A4 4562/4885CYP1A2 3484/4885CYP2D6 4316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.